Why the study?
Does ramipril reduce death, myocardial infarction, and stroke in high-risk patients without low ejection fraction or heart failure?
Does ramipril reduce death, myocardial infarction, and stroke in high-risk patients without low ejection fraction or heart failure?
Ramipril significantly reduces death, myocardial infarction, and stroke in high-risk patients without heart failure or low ejection fraction.
Supports ramipril in high-risk patients without HF or low EF; extends ACEI benefits beyond systolic dysfunction.
Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
No takes yet. Share an insight, caveat, or question.
Salim Yusuf (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: